Several sell-side analysts agree with our assessment including Oppenheimer (PT=$9), Canaccord Genuity (PT=$13) and HC Wainwright (PT=$18), all of which suggested buying the stock within past week. There is high short interest in the stock and any good news like the upcoming sNDA decision of Trulance in IBS-C should provide a boost to the stock price.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.